{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Alimera Sciences, Inc."},"Symbol":{"label":"Symbol","value":"ALIM"},"Address":{"label":"Address","value":"6120 WINDWARD PARKWAY SUITE 290, ALPHARETTA, Georgia, 30005, United States"},"Phone":{"label":"Phone","value":"+1 678 990-5740"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Alimera Sciences is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN(R) is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. A $2B global market, DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema leading to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology."},"CompanyUrl":{"label":"Company Url","value":"https://www.alimerasciences.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Philip John Ashman","title":"COO &amp; SVP-Commercial Operations Europe"},{"name":"Richard S. Eiswirth","title":"President, Chief Executive Officer &amp; Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}